These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14980886)

  • 1. Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
    Harv Heart Lett; 2004 Feb; 14(6):5. PubMed ID: 14980886
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholesterol: low is good. Lower is better. PROVE IT has doctors rethinking how to treat high cholesterol and what's a good target.
    Harv Heart Lett; 2004 May; 14(9):3. PubMed ID: 15153372
    [No Abstract]   [Full Text] [Related]  

  • 3. New LDL goals: even lower?
    Johns Hopkins Med Lett Health After 50; 2004 Jul; 17(5):1-2, 7. PubMed ID: 15233099
    [No Abstract]   [Full Text] [Related]  

  • 4. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins for high-risk patients without heart disease or high cholesterol.
    Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400
    [No Abstract]   [Full Text] [Related]  

  • 6. How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke.
    Health News; 2004 Oct; 10(10):6. PubMed ID: 15584114
    [No Abstract]   [Full Text] [Related]  

  • 7. [Lowering of cholesterol. What role is played by the choice of statins?].
    März W
    MMW Fortschr Med; 2004 Sep; 146(35-36):55. PubMed ID: 15540544
    [No Abstract]   [Full Text] [Related]  

  • 8. [Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
    Einecke D
    MMW Fortschr Med; 2004 Mar; 146(13):4-5. PubMed ID: 15219114
    [No Abstract]   [Full Text] [Related]  

  • 9. "Major surprise" in a new study means likely changes in treatment.
    Heart Advis; 2004 May; 7(5):2. PubMed ID: 15195616
    [No Abstract]   [Full Text] [Related]  

  • 10. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    März W
    MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
    MMW Fortschr Med; 2001 Apr; 143(14):44. PubMed ID: 11340911
    [No Abstract]   [Full Text] [Related]  

  • 12. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol limbo: How low should the bar go. Ratcheting down LDL to extra-low levels with high-dose statins seems to work wonders.
    Harv Health Lett; 2004 May; 29(7):1-2. PubMed ID: 15153394
    [No Abstract]   [Full Text] [Related]  

  • 14. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 15. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
    Ray KK; Cannon CP; Ganz P
    Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].
    Nissen S
    MMW Fortschr Med; 2004 Mar; 146(13):65. PubMed ID: 15219143
    [No Abstract]   [Full Text] [Related]  

  • 18. Synthetic statins: more data on newer lipid-lowering agents.
    Wierzbicki AS
    Curr Med Res Opin; 2001; 17(1):74-7. PubMed ID: 11464449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.